The European and Developing Countries Clinical Trials Partnership (EDCTP) has given a grant of β¬10 million over five years to βWANECAM 2β to conclude production of new malaria drug.
WANECAM 2 is a unique collaboration between antimalarial drug researchers in Africa and Europe from ten academic institutions, a pharmaceutical company, Novartis, and a not-for-profit product development partnership (PDP), Medicines for Malaria Venture.
The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation.
KAF156 has demonstrated the potential to treat resistant malaria and to be administered as a single dose.
